ECL welcomes the initiative to build patient-centred Pharma Strategy with strong emphasis on addressing unmet need & achieving greater medicines access, availability, affordability and sustainability of health systems. For key policy recommendations, see page 12-18 of our BCP vision: https://bit.ly/3drdqPp

Strengths:

1. Ensure timely access to safe, quality and affordable medicines and financial sustainability of MS’ health systems. ECL appreciates recognition of (i) high medicines prices and its negative impact on health systems and patients; (ii) need for enhanced cooperation in HS, HTA and P&R; (iii) need for increased transparency throughout the sector, including on costs and prices of medicines. ECL recommends to:

   i. Prevent misuse and overuse of the orphan status and ensuring the right balance between investment in orphan medicines, particularly where there is no treatment alternative, and preventing unintended effects on affordability;
   
   ii. Conduct a study on the role of price transparency, with attention to robust methods for the calculation of R&D and production costs, and suggesting ways toward EU-wide implementation of the WHO Transparency Resolution;
   
   iii. Measure and disclosing the extent of public investment in R&D at both the EU and MS level and creating prerequisites for public investment to ensure publicly funded products are available at an affordable price;
   
   iv. Establish High-Level multi-stakeholder WG to discuss a fair price definition and sustainable pricing models.

2. The need for new therapies to be clinically better than existing alternatives as well as cost-effective. It is crucial to align patient and public health needs with development of new medicines. It is important to maintain high regulatory and HTA standards. ECL recommends:

   i. Full implementation of the Clinical Trials Regulation as soon as possible;
   
   ii. Close collaboration between public authorities, patients and HCPs to identify and financially support areas of unmet medical need and low financial interest;
   
   iii. High quality benefit-risk assessment of patient-relevant endpoints before granting market access, stressing the need for surrogate endpoints in CTs to be accompanied by hard endpoints reflecting improvements in overall survival and quality-of-life measures;
   
   iv. Systematic collection and submission of real-world evidence (including OS, adverse reactions and QoL improvements) once the medicine enters the market;
   
   v. Pooling of resources and international cooperation between EU MS to prepare health systems for (i) the arrival of new medicines and technologies, (ii) conducting high quality HTA and (iii) sharing information about prices and pricing and reimbursement strategies, in order to enhance MS’ ability to (a) prioritise medicines with higher clinical value, (b) review and adjust prices based on new evidence, and (c) effectively negotiate the prices of medicines.
3. Addressing and preventing medicine shortages. One country cannot address this growing problem alone. Please see our recommendations on how to prevent and manage medicine shortages in Europe here: https://bit.ly/2YqgxCE

Shortcomings:

1. More attention should be given to the need to maintain a robust regulatory environment for medicines coming to the EU market. This includes new ways of collecting evidence on medicines efficacy and safety (also post approval - RWE) and data requirements for developers which include regulators/payers demands early in the medicines R&D process. Connecting this Strategy with the recently published EMA Regulatory Science strategy is crucial.

2. The negative impact of IP protection and incentives on the affordability of products should be elaborated.

3. Acknowledging public investment in medical R&D and attaching it to conditionalities related to open science and affordability is key, e.g., for products funded through EU4Health or HEU.

4. Role and responsibilities of the EMA in the development of the Strategy should be clarified and enhanced

Introduction

The EU strives to be a frontrunner in ensuring universal health coverage. In addition, it is a global leader in healthcare research and development and a major trading partner in pharmaceuticals and medical technologies. People across the EU expect to benefit from equal access to safe, state-of-the-art and affordable new and established therapies. Medicines play an important role in this regard, as they offer therapeutic options for diagnosis, treatment and prevention of diseases.

The unprecedented coronavirus pandemic (COVID-19) clearly demonstrates the need to modernise the way the EU ensures that its citizens get the medicines they need. Although this has been thrown into sharp relief by the coronavirus pandemic, it is not a new problem: even prior to the pandemic we witnessed shortages of essential medicines, such as cancer treatments, vaccines and antimicrobials. This calls for a thorough examination of how the supply chain - from the importing of active ingredients, raw materials, and medicines from third countries to internal EU production and distribution – can be made more secure and reliable.

Securing the supply of medicines is not only about existing therapies. There is also a need to ensure that the European pharmaceutical industry remains an innovator and world leader. Innovative technologies such as artificial intelligence as well as data collected from clinical experience (“real world data”) have the potential to transform therapeutic approaches and the way medicines are developed, produced, authorised and placed on the market and used. Innovation needs to be focused on areas of most need.

At the same time, more must be done to ensure that innovative and promising therapies reach all patients who need them: at present, this is not the case, with patients in smaller markets being particularly affected. Health systems, which are also seeking to ensure their financial and fiscal sustainability, need new therapies that are clinically better than existing alternatives as well as cost effective.

Finally, we are more aware than ever of the need to reduce the environmental footprint of medicines.

All these challenges will be addressed in the forthcoming EU Pharmaceutical Strategy, which should cover the whole life-cycle of pharmaceutical products from scientific discovery to authorisation and patient access.

More information on the context of the initiative, on the challenges identified so far and on the objectives can be found in the roadmap (https://ec.europa.eu/info/law/better-regulation/have-your-say/initiatives/12421-Pharmaceutical-Strategy-Timely-patient-access-to-affordable-medicines). Whether you are a concerned citizen or a professional in the area of medicines we would like you to let us know if you share our
objectives, what actions we should focus on and whether there are any additional aspects that we should cover.

After some introductory questions about yourself, the questionnaire continues with questions on the Pharmaceutical strategy.

When replying, please keep in mind that the questions in this survey were developed to address the long-standing issues identified in the EU pharmaceuticals system. These may be related to the problems arising from the coronavirus pandemic but are broader than that. The end of the survey includes dedicated questions on coronavirus related issues.

Please note that in this questionnaire, we do not intend to obtain data relating to identifiable persons. Therefore, in case you will describe a particular experience or situation, please do it in a way that will not allow linking to a particular individual, whether it is you or somebody else.

We thank you in advance for your time and input.

---

**About you**

*Language of my contribution*

- Bulgarian
- Croatian
- Czech
- Danish
- Dutch
- **English**
- Estonian
- Finnish
- French
- Gaelic
- German
- Greek
- Hungarian
- Italian
- Latvian
- Lithuanian
- Maltese
- Polish
- Portuguese
Romanian
Slovak
Slovenian
Spanish
Swedish

* I am giving my contribution as
  - Academic/research institution
  - Business association
  - Company/business organisation
  - Consumer organisation
  - EU citizen
  - Environmental organisation
  - Non-EU citizen
  - Non-governmental organisation (NGO)
  - Public authority
  - Trade union
  - Other

* Organisation name

  255 character(s) maximum

  Association of European Cancer Leagues (ECL)

* Organisation size

  - Micro (1 to 9 employees)
  - Small (10 to 49 employees)
  - Medium (50 to 249 employees)
  - Large (250 or more)

Transparency register number

  255 character(s) maximum

  Check if your organisation is on the transparency register. It’s a voluntary database for organisations seeking to influence EU decision-making.

  19265592757-25

* Which stakeholder group do you represent?
Individual member of the public
Patient or consumer organisation
Healthcare professional
Healthcare provider organisation (incl. Hospitals, pharmacies)
Healthcare pricing & reimbursement body and/or final payer
Centralised health goods procurement body
Health technology assessment body
Academic researcher
Research funder
Learned society
European research infrastructure
Other scientific organisation
Environmental organisation
Pharmaceuticals industry
Chemicals industry
Pharmaceuticals traders/wholesalers
Medical devices industry
Public authority (e.g. national ministries of health)
EU regulatory partner / EU institution
Non-EU regulator / non-EU body
Other (please specify)

Are you responding on behalf of a Small or Medium Sized Enterprise?
Yes
No

* First name
Wendy

* Surname
YARED

* Email (this won't be published)
ecloffice@europeancancerleagues.org
<table>
<thead>
<tr>
<th>Country of origin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Please add your country of origin, or that of your organisation.</td>
</tr>
</tbody>
</table>

- Afghanistan
- Åland Islands
- Albania
- Algeria
- American Samoa
- Andorra
- Angola
- Anguilla
- Antarctica
- Antigua and Barbuda
- Argentina
- Armenia
- Aruba
- Australia
- Austria
- Azerbaijan
- Bahamas
- Bahrain
- Bangladesh
- Barbados
- Belarus
- Djibouti
- Dominica
- Dominican Republic
- Ecuador
- Egypt
- El Salvador
- Equatorial Guinea
- Eritrea
- Estonia
- Eswatini
- Ethiopia
- Falkland Islands
- Faroe Islands
- Fiji
- Finland
- France
- French Guiana
- French Polynesia
- French Southern and Antarctic Lands
- Gabon
- Georgia
- Libya
- Liechtenstein
- Lithuania
- Luxembourg
- Macau
- Madagascar
- Malawi
- Malaysia
- Maldives
- Mali
- Malta
- Marshall Islands
- Martinique
- Mauritania
- Mauritius
- Mayotte
- Mexico
- Micronesia
- Moldova
- Monaco
- Mongolia
- Saint Martin
- Saint Pierre and Miquelon
- Saint Vincent and the Grenadines
- Samoa
- San Marino
- São Tomé and Príncipe
- Saudi Arabia
- Senegal
- Serbia
- Seychelles
- Sierra Leone
- Singapore
- Sint Maarten
- Slovakia
- Slovenia
- Solomon Islands
- Somalia
- South Africa
- South Georgia and the South Sandwich Islands
- South Korea
- South Sudan
Belgium  Germany  Montenegro  Spain
Belize   Ghana     Montserrat  Sri Lanka
Benin    Gibraltar  Morocco    Sudan
Bermuda  Greece     Mozambique  Suriname
Bhutan   Greenland  Myanmar   Svalbard and Jan Mayen
Bolivia  Grenada    Namibia    Sweden
Bonaire Saint Eustatius and Saba Namibia    Switzerland
Bosnia and Herzegovina Nepal    Syria
Botswana  Guam        Netherlands  Taiwan
Bouvet Island Guatemala  New Caledonia Tajikistan
Brazil   Guernsey     New Zealand  Tanzania
British Indian Ocean Territory Guatemala  Nicaragua  Thailand
British Virgin Islands Guyana     Niger    The Gambia
Brunei   Haiti       Nigeria     Timor-Leste
Bulgaria  Heard Island and McDonald Islands Niue    Togo
Burkina Faso Honduras  Norfolk Island  Tokelau
Burundi   Hong Kong   Northern Mariana Islands Tonga
Cambodia  Hungary    North Korea  Trinidad and Tobago
Cameroon  Iceland     North Macedonia Tunisia
Canada   India       Norway
Cape Verde Indonesia  Oman
Cayman Islands Iran  Pakistan

Brunei
Bonaire Saint Eustatius and Saba
Bosnia and Herzegovina
Botswana
Bouvet Island
Brazil
British Indian Ocean Territory
British Virgin Islands
Brunei
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Cayman Islands
The Commission will publish the responses to this public consultation. You can choose whether you would like your details to be made public or to remain anonymous.

- **Anonymous**
  Only your type of respondent, country of origin and contribution will be published. All other personal details (name, organisation name and size, transparency register number) will not be published.

- **Public**
  Your personal details (name, organisation name and size, transparency register number, country of origin) will be published with your contribution.

- I agree with the [personal data protection provisions](#)

---

**International dependency and manufacturing**

The EU is increasingly dependent on active ingredients originating from outside the EU. This has implications, including as regards increasing the risk of quality issues and shortages of medicines. The recent outbreak of COVID-19 shows that a disruption in the pharmaceutical products supply chain originating from outside the EU could present a major health security issue.

1. What type of EU action or initiative do you consider helpful to incentivise the production of active pharmaceutical ingredients for essential medicines (e.g. antibiotics, oncology medicines) in the EU?

   *800 character(s) maximum*

   We need to ensure medicines are available to those who need them. In terms of production, we need to focus on diversification of raw materials and API producers/sources (could also be outside of the EU). Any production in the EU should meet EU environmental, social regulations and occupational standards and should not pose threats to affordability of the product.

2. What action do you consider most effective in enhancing the high quality of medicines in the EU?

   *between 1 and 1 choices*

   - [ ] Stronger enforcement of the marketing authorisation holder responsibilities
   - [ ] Increased official controls in the manufacturing and distribution chain
   - [ ] Other (please specify)
   - [ ] I don’t know

---

**Access to affordable medicines**
A shortage of a medicine occurs when there are not enough medicines in a country to treat every patient with a given condition. Shortages can have a big impact on patients if their treatment is delayed because there is no alternative, or the alternative is not suited to their needs.

3. Are you concerned about medicines shortages in the EU?
   - I am concerned
   - I am not concerned
   - I have no particular opinion

If you wish, please elaborate your reply.

500 character(s) maximum

- EAHP: 47% hospital pharmacists said oncology medicines most commonly in shortage (compared to 39% in 2018)
- French Cancer League: 60% oncologists claim that shortages have worsened over the past 10 years = cancer progression, worsening prognosis, emotional distress for patients

4. Which actions do you think would have the biggest impact on reducing shortages in the EU?

at most 3 choice(s)

- ✔️ Stronger obligations on medicines producers, and other players in the supply chain to ensure medicines are available
- ✔️ Transparent information exchange among authorities on medicine stocks available in each country
- ✔️ Increased cooperation among public authorities/national governments on shortages
- □ Multi-lingual packaging and electronic product information leaflets facilitating purchasing in different countries
- □ Providing incentives to companies to increase the production of medicines in the EU
- □ Inform on and make available to patients suitable substitutes for medicines that are at risk of shortage
- □ Other (please specify).

Innovative medicines have to undergo a centralised EU-wide marketing authorisation. Companies often initially market them in a limited number of EU countries. It can take several years before patients in the other EU countries have access to those products.
5. Do you think that companies that apply for and receive an EU-wide marketing authorisation should be required to make that product available in all EU countries?

- I agree
- I neither agree or disagree
- I disagree
- I don't know

If you wish, please elaborate your reply.

500 character(s) maximum

- This would accelerate in some countries (esp. secondary/smaller markets);
- Feasibility needs to be taken into account e.g., regarding the capacity to launch products for smaller companies as well as available treatment options and demand of the different market;
- As a solution, maximum delays measures could be implemented;
- ECL support's Commission's pilot project to map market launches intentions.

In recent years, there has been an increase in the number of medicines withdrawn from the market upon decisions by the manufacturers.

6. Do you have an opinion on the reasons for these market withdrawals?

- Yes
- No

If yes, please elaborate.

500 character(s) maximum

- Divestment in cheap medicines and investment in more profitable areas;
- Not profitable to keep manufacturing;
- Price gouging e.g., to impose price increases, Aspen threatened to withdraw medicines in some MS and has done so in certain cases;
- Poor supply chain management affect manufacturing sites - important to control; regulatory flexibilities (by EC during crisis to accelerate production) when facing shortages might further create not resolve problems.

7. Are you aware of patients not receiving the medicine they need because of its price?

- Yes
- No

If you wish, please elaborate your reply.

500 character(s) maximum

- Increasingly becoming an issue in Europe, both as to the per patient treatment price and the budget impact of treating all relevant patients;
- Crowdfunding for innovative treatments (e.g., zolgensma);
8. Do you think that medicine prices are justified, taking into consideration the costs associated to their development and manufacturing?

☐ Yes
☐ No
☐ I don’t know

If you wish, please elaborate your reply. 
500 character(s) maximum

- Prices and costs are not transparent to the payers/public = difficult to justify price based on cost information;
- Value documentation of new medicines is often too scarce for payers to be able to evaluate if it’s worth paying for;
- Enhanced transparency is needed to be able to justify prices;
- Price needs to reflect added benefit, related costs and ability to pay;

High prices for new medicines put pressure on public health spending. The costs for research and development are not publically disclosed and there is no agreement on how to calculate such costs. In certain cases, some EU countries join forces to increase their negotiating power when discussing prices with pharmaceutical companies. Individual pricing decisions in some EU countries may affect others. As an example, some EU countries limit the prices of medicines by linking that price to average prices in other EU countries (we call this “external reference pricing”- ERP). Because of ERP, a pricing decision in one EU country can inadvertently affect the prices in others. Once patents and other forms of market protection expire, generic and biosimilar medicines can enter the market and compete with the existing ones, this also typically brings down prices. Finally, there are plans to strengthen support to EU countries to work with each other on the clinical effectiveness of new medicines compared to existing alternatives, simply put how much better a medicine works compared to another one. This is part of the so called “health technology assessment” process.

9. What are the most effective ways the EU can help improve affordability of medicines for health systems?

at most 3 choice(s)

☐ Support the EU countries in better assessing and/or evaluating the value of medicines, meaning the effectiveness of a (new) medicine compared with existing ones
☐ Help EU countries share experiences and pool expertise on pricing and procurement methods
☐
Better coordination among EU countries to ensure that pricing decisions taken by one EU country do not lead to negative impacts on patient access in another EU country

- Facilitate, market entry and a healthy market functioning for generics and biosimilars
- More transparency on how the cost of a medicine relates to the cost of its research and development
- There should be a fair return on public investment when public funds were used to support the research and development of medicines
- I don't know
- Other

* Please explain.  

100 character(s) maximum

All above actions would help improve affordability, see ECL’s paper here: bit.ly/price-fair

---

**Innovation in early development and authorisation**

The European Commission actively supports health research and development through various funding mechanisms (e.g., Multiannual Financial Framework, Horizon 2020, Innovative Medicines Initiative partnership) and through collaborations between academia, healthcare systems and industry. Furthermore, the EU pharmaceutical legislation includes incentives to stimulate the development of innovative new medicines in areas such as paediatric and rare diseases; and market exclusivity rights to industry.

10. What actions at EU level do you consider most effective in supporting innovative research and development of medicines?

at most 3 choice(s)

- Make the legislative framework more adaptive to new technologies and advances in science
- Provide more public funding for research
- Support (including through funding) private-public partnerships
- Support (including through funding) the creation of start-ups in medical research

✔️
Foster research collaboration between universities, research centres and industry

☑ Provide research and development incentives in the form of intellectual property or market exclusivity rights for pharmaceutical companies investing in research

☑ Simplify the requirements for the conduct of clinical trials

☑ Other (please specify)

☐ I don’t know

Please elaborate your reply.

100 character(s) maximum

Allow academia register treatments @EMA; Fund pilots to award R&D models that ensure affordability

Expected return on investment in research and development for the pharmaceutical industry depends also on the expected volume of sales; this seems to be one of the root causes of limited availability of certain medicines (e.g. medicines for rare diseases or medicines for children).

11. What do you consider are the most effective actions related to research and development of medicines in areas where there are limited or no therapeutic options (unmet needs)?

at most 3 choice(s)

☐ Provide market protection (protect a new medicine from competition)

☐ Provide intellectual property protection

☐ Provide data protection (protection of the data related to a medicine’s clinical trials)

☑ Agree on a common understanding on what are the areas of unmet need in the EU

☑ Funding more targeted research at EU level

☑ Funding more targeted research at national level

☐ Provide national schemes to support companies economically

☐ I don’t know / no opinion

☐ Other (please specify)

The health sector is becoming more digitised, thanks to the increased availability and collection of health data from sources such as electronic health records, patient and disease registries and mobile apps (i.e.
real world data) and through the use of artificial intelligence (AI) (i.e. systems that display intelligent behavior and the use of complex algorithms and software in the analysis of complex health data). These developments, combined with real world data are transforming health, including the discovery of medicines.

12. Which opportunities do you see in digital technologies (such as artificial intelligence and use of real world data) for the development and use of medicines?

600 character(s) maximum

Uptake of personalised medicines is hampered by uncertainty re outcomes. We need rigorous methodology reevaluation of such treatment principles. Personalised medicines require large datasets for advanced statistical analysis, learning and large-scale collaboration. Medicine developers use real world evidence (RWE) and AI to support clinical trial designs. This supports evidence base for decision makers, ensures that CTs are conducted in real-life settings and new treatments reach patients faster.

13. Which risks do you see in digital technologies (such as artificial intelligence and use of real world data) for the development and use of medicines?

600 character(s) maximum

Very important is to ensure data security, safety and high ethical standards. Studies using RWE, which often consist of multiple RWD sources, should be conducted with the most rigorous design possible, without bias and using appropriate analytic approaches. Advancements in the methodology and set up of trials in the area of personalised medicine must be developed in close collaboration with decision-makers and patients.

Continuous manufacturing, advanced process analytics and control, 3D printing and portable/modular systems, may revolutionise the way medicines are manufactured.

14. Are you aware of any obstacles in the EU in taking advantage of technological progress in the manufacturing of medicines?

- Yes
- No
- I don't know

If yes, could you please specify.

500 character(s) maximum

Personalised medicines consist of pharmaceutical and a companion diagnostic measure, whereas legislation concern either the pharmaceutical or the diagnostic measure. Clinical use of pers med requires prescription of both and the treatment effect largely depend on the diagnosis. Differences in development and authorisation for medicines and devices make it difficult to synchronise timing. European guidelines for co-development of both and co-ordination of approval procedures should be developed.

Clinical trials are investigations in humans to discover if a new medicine is safe and effective. Clinical trials can also be used to test if a new treatment is more effective and/or safer than the standard treatment. Finally, so called "pragmatic clinical trials" can be conducted to compare the safety and effectiveness of different standard treatments in real world setting.
15. How could clinical trials in the EU be driven more by patients’ needs while keeping them robust, relevant and safe for participants?

(at most 3 choice(s))

☐ By providing more national support for the conduct of so-called “pragmatic trials” with the aim to optimise treatment to patients
☐ By better coordination for larger trials comparing different treatment strategies (covering medicines and other treatments such as surgery, radiotherapy, physiotherapy)
☐ By providing support for non-commercial organisations to conduct clinical trials in fields where financial interest is weaker
☐ By involving patients’ experiences in early phases of medicine design (e.g. factor-in how the disease affects their lives and develop medicines to target symptoms that are particularly important to patients)
☐ By designing more trials that collect information on medicine tolerability or the impact of a treatment on the quality of life
☐ By taking into consideration during the design of a trial the burden of trial participation on patients’ life
☐ Other (please specify).

Certain medicines are developed based on genes, cells or tissue engineering. Some of these products are developed in hospitals. These are covered by the notion of advanced therapy medicines.

16. Is the current legal framework suitable to support the development of cell-based advanced therapy medicines in hospitals?

☐ I strongly agree
☐ I partially agree
☐ I disagree
☐ I don’t know

* If you responded partially agree or disagree, please provide examples of changes that, in your view, would be required to support the development of these products.

500 character(s) maximum

Cell-based therapies present a turning point, but their complexity challenges production and uptake. E.g., CAR-T trials are conducted in US and China and manufacturing sites are only starting to be set up in Europe. EMA and HTA must collaborate on evaluation of such treatments, decide relevant endpoints, support trials and production, collect RWE (safety & efficacy data). Hospital exemptions shall be explored re these products to manufacture close to point of care and enable affordable access.
Environmental sustainability of medicines and health challenges

Residues of several medicines have been found in surface and ground waters, soils and animal tissues across the Union. As of yet, no clear link has been established between medicine residues present in the environment and direct impacts on human health. However, the issue cannot be ignored and there is a need for a precautionary approach.

17. What actions at EU level do you consider most effective in limiting the negative environmental impact of medicines?

at most 3 choice(s)

- Cleaner manufacturing processes
- Enhanced application of the polluter pays principle
- Review the way the Environment Risk Assessment of a medicine is conducted and its consequences on the authorisation process
- Clear labelling of environmental risks to allow informed choices among equivalent therapeutic options
- Reference to environmental risks in advertising for over-the-counter medicines
- Make medicines known to pose an environmental risk available by prescription only
- Strict disposal rules for unused medicines
- Prescribe medicines only when it is absolutely necessary (more prudent use)
- Medicines dispensed to patients in the quantity actually needed (e.g. number of pills, volume of solution)
- Enhanced wastewater treatment if certain residues could be better removed
- Other (please specify)

Antimicrobial resistance (AMR) is the ability of microorganisms (such as bacteria, viruses, fungi or parasites) to survive and grow in the presence of medicines. It reduces progressively the effectiveness of antimicrobials and is caused, among other things, by extensive and improper use of antimicrobial medicines. Antimicrobials include antibiotics, which are substances that fight bacterial infections. AMR can lead to problems such as difficulties to control infections, prolonged hospital stays, increased economic and social costs, and higher risk of disease spreading. AMR is one of the most serious and urgent public health concerns.

18. Which actions do you think would have the biggest impact on fighting AMR concerning the use of medicines for patients?

at most 3 choice(s)

- More prudent use of antimicrobials (if necessary through restrictions on prescriptions)
- Improve the treatment of wastewater and/or manure to lower the levels of antimicrobials
- Raise citizens' and healthcare practitioners' awareness by informing them on appropriate use of antimicrobials and the correct disposal of unused medicines
- Introduce an obligation to use diagnostic tests before prescribing antimicrobials, for example to verify whether it is a bacterial infection before prescribing antibiotics and to define the most adequate antibiotic
- Public finance research and innovation on new antimicrobials, their alternatives and diagnostics
- Encourage public health campaigns that prevent infection through better general health including increased immunity
- Encourage public health campaigns that prevent infection through the use of vaccines
- Encourage better hygiene measures in hospitals
- Other (please specify)
- I don't know

Innovation in antimicrobials is limited. For example, no new classes of antibiotics have been discovered for decades. Restricting the use of antibiotics to minimise the risk of developing resistance is a commercial disincentive for investment, as potential investors are concerned that their investment will not be profitable.

19. Where, in your view, should the EU focus its support for the creation of new antimicrobials or their alternatives?

- Support academia for researching/discovering new antimicrobials or their alternatives
- Support industry for developing new antimicrobials or their alternatives
- Provide specific support to small and medium-sized enterprises (SMEs)
- Other (please specify)
- I don't know

Health threats such as the coronavirus disease test the limits of public health systems, the pharmaceutical industry and of the pharmaceutical legislation. From the beginning of the coronavirus (COVID-19) pandemic, the EU has taken measures to coordinate a response, which includes actions ensuring the availability of medicines.

20. How has the coronavirus (COVID-19) pandemic affected you in relation to access to medicines and treatments?
Interruptions and delays in the delivery of different interventions has compromised patient safety and the efficacy of their treatment. Patients experienced disruptions in the supply of medications (including anaesthetics and curare), discontinuation of chemotherapy and radiotherapy as well as of the operating capacity of hospitals.

21. In your opinion and based on your experience, what can the EU do to prepare for and manage such a situation better in the future in relation to pharmaceuticals?

Develop European medicine shortages prevention and management plans; Ensure early warning system and reinforce reporting obligations for developers and wholesalers to supply the market; Provide equitable support for European countries prioritising those with limited resources and strained health systems. Resources from the EU4Health programme (2021-2027) and Coronavirus Response Investment Initiatives funds must be front-loaded to ensure quick and targeted interventions are made to protect cancer patients and to prevent a negative impact in the delivery of cancer services during epidemics.

Summary question

22. While the Commission is working on improving the EU pharmaceuticals framework, which areas of work do you find most urgent?

- Improve patients’ access to medicines
- Reduce shortages
- Help national authorities ensure affordability for patients and increase health systems sustainability
- Support innovation for unmet needs
- Use of digitalisation to develop medicines
- Help reduce anti-microbial resistance
- Reduce the dependency on essential active ingredients and medicines produced outside the EU
- Environmental sustainability of medicines
- I don’t know
- Other (please specify)

23. If you were asked before the coronavirus (COVID-19) pandemic, would you have responded differently to any of the previous questions?

- Yes

No

☐ I don't know

24. Is there anything else you would like to add that has not been covered in this consultation?

900 character(s) maximum

For more elaborate policy recommendations, please see attached ECL’s position paper with policy recommendations covering the below areas:

- Medicine Shortages
- New ways of organising and incentivising R&D
- Clinical trials
- Medicines authorisation
- Orphan and paediatric medicines
- International collaboration in horizon scanning, HTA and pricing
- Fair pricing of medicines


You may upload a position paper here.

The maximum file size is 1 MB

Only files of the type pdf, txt, doc, docx, odt, rtf are allowed

[753e64c4-2e79-418e-a175-38bf610c9050/ECL_Pharma_Strategy_Paper_-_DIGITAL__new_-compressed.pdf]

Contact

EU-PHARMACEUTICAL-STRATEGY@EC.EUROPA.EU